New biologic KD6005 tested in first human trial for rheumatoid arthritis
NCT ID NCT06213259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new biologic drug called KD6005 in 73 people: first in healthy volunteers, then in patients with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug. It is too soon to know if KD6005 works, but this study is a necessary first step toward possibly finding a new treatment option for rheumatoid arthritis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KD6005 (a biologic drug given as an injection)
What this could lead to
If this early study shows KD6005 is safe and well-tolerated, it could pave the way for larger trials to see if it helps control rheumatoid arthritis symptoms.
What could go wrong
This is a very early Phase 1 trial with only 73 participants, focused on safety, not effectiveness. The drug may not work in larger studies or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, China